Background: Chemotherapy with multiple drugs has been a crucial step in the treatment of Multiple Myeloma producing a high deep response rate and improving progression-free survival and overall survival. The efficacy of bortezomib in the induction of remission has been demonstrated in different studies. Cytotoxic drugs such as Doxorubicin, Cyclophosphamide or Thalidomide have been combined with Bortezomib / Dexamethasone. There are few randomized studies comparing remission with Bortezomib / Dexamethasone with Cyclophosphamide, Doxorubicin or Thalidomide inductions treatments.

The purpose of this study was to report the therapeutic results obtained from prospective protocols at the Hematology Service of our hospital, over the course of this century, before new drugs were used. All patients underwent chemotherapy (only one recent group also received rituximab).All LCL patients taken care of at the Hematology Service of the National Medical Center (CMN) "20 de Noviembre", ISSSTE. Patients included in this study were diagnosed with LCL and met the following criteria: persistent lymphocytosis above 5 × 109/L, for more than three months; typical lymphocytic morphology, with less than 10% of immature forms; immunophenotype of B strain with CD5, CD19, CD 79a, CD 20, CD22, CD23, CD24, CD25 + low-intensity SmIg; 30%+ lymph cells in the bone marrow.

No abstract